Literature DB >> 19026148

Mortality in ankylosing spondylitis.

J Zochling1, J Braun.   

Abstract

Ankylosing spondylitis (AS) is a chronic inflammatory rheumatic disease which causes pain along with loss of physical function and quality of life over many years. It has also been shown to increase mortality compared to the general population, independent of treatment modalities. Cardiovascular deaths are increased, and recent studies suggest both an abnormality of lipid regulation and microvascular changes. Increased rates of suicide, accidental death, and alcohol-related deaths have also been reported. This review examines rates and causes of increased mortality in AS and highlights a need to focus on cardiovascular risk factors and psychological health in addition to physical disability in patients with AS.

Entities:  

Mesh:

Year:  2008        PMID: 19026148

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  10 in total

1.  Mortality in patients with ankylosing spondylitis in Argentina.

Authors:  Emilio Andres Buschiazzo; Emilce Edith Schneeberger; Fernando Andres Sommerfleck; Cesar Ledesma; Gustavo Citera
Journal:  Clin Rheumatol       Date:  2016-07-04       Impact factor: 2.980

Review 2.  Managing premature atherosclerosis in patients with chronic inflammatory diseases.

Authors:  Alexandra Legge; John G Hanly
Journal:  CMAJ       Date:  2018-04-09       Impact factor: 8.262

3.  The prevalence of HLA-B27 in the US: data from the US National Health and Nutrition Examination Survey, 2009.

Authors:  John D Reveille; Rosemarie Hirsch; Charles F Dillon; Margaret D Carroll; Michael H Weisman
Journal:  Arthritis Rheum       Date:  2012-05

4.  Plasma asymmetric dimethylarginine (ADMA) levels and atherosclerotic disease in ankylosing spondylitis: a cross-sectional study.

Authors:  Gian Luca Erre; Pietro Sanna; Angelo Zinellu; Alessandra Ponchietti; Patrizia Fenu; Salvatore Sotgia; Ciriaco Carru; Antonello Ganau; Giuseppe Passiu
Journal:  Clin Rheumatol       Date:  2010-10-14       Impact factor: 2.980

5.  Safety and clinical efficacy of golimumab in the treatment of arthritides.

Authors:  Ismail Simsek; Yusuf Yazici
Journal:  Drug Healthc Patient Saf       Date:  2010-09-28

6.  Echocardiographic and Electrocardiographic Findings in Patients with Ankylosing Spondylitis without Cardiovascular Risk Factors.

Authors:  Simin Almasi; Behzad Farahani; Niloufar Samiei; Yousef Rezaei; Habib Mahmoodi; Mostafa Qorbani
Journal:  J Tehran Heart Cent       Date:  2020-04

7.  LncRNA MEG3 inhibits the inflammatory response of ankylosing spondylitis by targeting miR-146a.

Authors:  Yehong Li; Shanshan Zhang; Cunxin Zhang; Meihong Wang
Journal:  Mol Cell Biochem       Date:  2020-01-01       Impact factor: 3.842

8.  Midlife Ankylosing Spondylitis Increases the Risk of Cardiovascular Diseases in Males 5 Years Later: A National Population-Based Study.

Authors:  Yao-Min Hung; Wei-Pin Chang; James Cheng-Chung Wei; Pesus Chou; Paul Yung-Pou Wang
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

9.  The risk of deliberate self-harm following a diagnosis of rheumatoid arthritis or ankylosing spondylitis: A population-based cohort study.

Authors:  Bindee Kuriya; Simone Vigod; Jin Luo; Jessica Widdifield; Nigil Haroon
Journal:  PLoS One       Date:  2020-02-21       Impact factor: 3.240

10.  Prevalence and impact of comorbidities in axial spondyloarthritis: systematic review and meta-analysis.

Authors:  Sizheng Steven Zhao; Selina Robertson; Tzvi Reich; Nicolas L Harrison; Robert J Moots; Nicola J Goodson
Journal:  Rheumatology (Oxford)       Date:  2020-10-01       Impact factor: 7.580

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.